Integrative genomic analysis of mouse and human hepatocellular carcinoma
暂无分享,去创建一个
O. Harismendy | H. Carter | L. Alexandrov | M. Karin | K. Taniguchi | Hayato Nakagawa | E. Seki | Michelle Dow | S. Shalapour | R. Pyke | J. Font-Burgada | B. Tsui | Joan Font-Burgada
[1] Tim F. Rayner,et al. Mutational landscape of a chemically-induced mouse model of liver cancer , 2018, bioRxiv.
[2] T. Ideker,et al. MHC-I Genotype Restricts the Oncogenic Mutational Landscape , 2017, Cell.
[3] Rohit Loomba,et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity , 2017, Nature.
[4] Jean-François Deleuze,et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis , 2017, Nature Communications.
[5] See-Tong Pang,et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia , 2017, Science Translational Medicine.
[6] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[7] Steven J. M. Jones,et al. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.
[8] P. Oliveira,et al. Animal models as a tool in hepatocellular carcinoma research: A Review , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[9] Anita Makri. Back to the future , 2017, Science.
[10] S. Elledge,et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.
[11] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[12] Mingming Jia,et al. COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..
[13] Hans Clevers,et al. Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.
[14] J. Martens,et al. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence , 2016, bioRxiv.
[15] Gábor E. Tusnády,et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.
[16] M. Stratton,et al. Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.
[17] Keith A. Boroevich,et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.
[18] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[19] G. Gores,et al. Hepatocellular carcinoma , 2016, Nature Reviews Disease Primers.
[20] Lloyd H. Michael,et al. The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.
[21] M. Stratton,et al. Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.
[22] Hayato Nakagawa. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. , 2015, World journal of hepatology.
[23] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[24] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[25] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[26] W. Sung,et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.
[27] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[28] M. Karin,et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.
[29] Deepak Mittal,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[30] D. Calvisi,et al. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. , 2014, The American journal of pathology.
[31] Kristen Jepsen,et al. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.
[32] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[33] A. Moorman,et al. Hepatitis C in the United States. , 2013, The New England journal of medicine.
[34] E. Wagner,et al. Mouse models for liver cancer , 2013, Molecular oncology.
[35] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[36] Kenji Suzuki,et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma , 2013, Medical Molecular Morphology.
[37] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[38] S. Imbeaud,et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.
[39] Benjamin J. Raphael,et al. De novo discovery of mutated driver pathways in cancer , 2011 .
[40] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[41] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[42] O. Andrisani,et al. Gene signatures in hepatocellular carcinoma (HCC). , 2011, Seminars in cancer biology.
[43] H. El‐Serag,et al. Surveillance for hepatocellular carcinoma: in whom and how? , 2011, Therapeutic advances in gastroenterology.
[44] R. Hruban,et al. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM) , 2010, Cancer biology & therapy.
[45] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[46] S. Akira,et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis , 2009, Proceedings of the National Academy of Sciences.
[47] Derek Y. Chiang,et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.
[48] F. Heindryckx,et al. Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.
[49] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[50] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[51] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[52] M. Stratton,et al. Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer , 2006, Genetics.
[53] F. X. Bosch,et al. Epidemiology of hepatocellular carcinoma. , 2005, Clinics in liver disease.
[54] S. Thorgeirsson,et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.
[55] Division on Earth. Guide for the Care and Use of Laboratory Animals , 1996 .